NEUP
Neuphoria Therapeutics IncKey Statistics
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc (Ticker: NEUP) is a pioneering biotechnology firm focused on developing groundbreaking therapies for mental health disorders through the use of psychedelic compounds and innovative drug delivery mechanisms. The company is dedicated to translating advanced research into effective treatments for significant unmet needs within the mental health space, thereby positioning itself as a frontrunner in the burgeoning psychedelic therapy market. With a strong pipeline of preclinical candidates, Neuphoria represents a compelling investment opportunity for institutional investors keen on engaging with emerging biotech trends poised to reshape mental health care. Its commitment to transformative therapeutic solutions underscores its potential to significantly impact the future landscape of mental health treatment.
Fundamentals
| Revenue (TTM) | $14.99M |
| Gross Profit (TTM) | $14.99M |
| EBITDA | $-1.20M |
| Operating Margin | -12.40% |
| Return on Equity | -26.10% |
| Return on Assets | -4.25% |
| Revenue/Share (TTM) | $5.76 |
| Book Value | $5.52 |
| Price-to-Book | 0.95 |
| Price-to-Sales (TTM) | 1.90 |
| EV/Revenue | 0.404 |
| EV/EBITDA | -0.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $5.39M |
| Float | $4.17M |
| % Insiders | 7.72% |
| % Institutions | 50.15% |
Historical Volatility
Volatility is currently contracting